top of page
The Professional Network for Healthcare Experts
Zealand Pharma licenses GLP-1/gastrin peptide platform to Elvinix for type 1 diabetes
Zealand Pharma has licensed its GLP-1/gastrin dual-agonist peptide platform to Elvinix for development as a potentially regenerative treatment for type 1 diabetes.
nuaxia
Sep 172 min read
Sernova and Seraxis agree merger to create BetaNova Biotherapeutics
Sernova and Seraxis have entered into a definitive merger agreement to create BetaNova Biotherapeutics, a new clinical-stage company focused on type 1 diabetes islet-cell replacement therapies.
nuaxia
Sep 92 min read
bottom of page